Hiromasa Horimoto

Constitutive aryl hydrocarbon receptor signaling constrains type I interferon–mediated antiviral innate defense

Taisho Yamada, Hiromasa Horimoto, Takeshi Kameyama et al. · Nature Immunology · 2016 · 253 citations

Antiviral Innate Defense, Viral Immunity, Immunology +9

Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C

Goki Suda, Mineo Kudo, Atsushi Nagasaka et al. · Journal of Gastroenterology · 2016 · 109 citations

Hemodialysis, Hepatology, Hepatitis C +12

The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma

Makoto Chuma, Shuhei Hige, Toshiya Kamiyama et al. · Journal of Gastroenterology · 2009 · 100 citations

Hepatitis D, Hepatology, Initial Curative Treatment +11

Side Effects and Good Effects from New Chemotherapeutic Agents

Masahiro Onozawa, Satoshi Hashino, Susumu Sogabe et al. · Journal of Clinical Oncology · 2005 · 35 citations

Medicine, Pharmacology, Side Effects +4

Efficacy of therapy for advanced hepatocellular carcinoma: Intra‐arterial 5‐fluorouracil and subcutaneous interferon with image‐guided radiation

Makoto Chuma, Hiroshi Taguchi, Yoshiya Yamamoto et al. · Journal of Gastroenterology and Hepatology · 2011 · 35 citations